XOMA

Companies XOMA

News XOMA

• XOMA Receives $750,000 Milestone Payment From AVEO Pharmaceuticals

  XOMA Ltd. announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a hu more

• Dr. Robert Gundel joins Amorfix as Vice President, Research & Development

  Amorfix Life Sciences announced that Robert Gundel, Ph.D., M.B.A., has been appointed the company's Vice President, Research & Development. Dr. Gundel has 25 years of drug development experience with both major pharmaceutical and smaller biotechnology companies focusing on therapeutic monoclonal an more

• XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director

  XOMA Ltd. announced that Steven B. Engle has been named president, chief executive officer and a member of the company's board of directors. Mr. Engle succeeds Jack Castello, the company's former president and chief executive officer, who announced his retirement plans earlier this year. Mr. Castell more

Publications XOMA

• Ligand Binding Assays in the 21st Century Laboratory—A Call for Change

  Ligand Binding Assays in the 21st Century Laboratory—A Call for Change Content Type Journal Article Category Editorial Pages 1-3 DOI 10.1208/s12248-012-9351-8 Authors Chad A. Ray, Pharmacokinetics Dynamics and Metabolism, Pfizer Worldwide Research & Development, La Jolla, California 921 more

• Ligand Binding Assays in the 21st Century Laboratory: Automation

  Ligand Binding Assays in the 21st Century Laboratory: Automation Content Type Journal Article Category Commentary Pages 1-12 DOI 10.1208/s12248-012-9323-z Authors Ago B. Ahene, XOMA Corporation, 2710 Seventh Street, Berkeley, California 94710, USA Chris Morrow, Genentech, South San Fra more

• Deal watch: XOMA and Servier to develop anti-IL-1β antibody for inflammatory diseases

  Deal watch: XOMA and Servier to develop anti-IL-1β antibody for inflammatory diseases Nature Reviews Drug Discovery 10, 166 (2011). doi:10.1038/nrd3390 XOMA and Servier have agreed to jointly develop and commercialize the interleukin-1β (IL-1β)-targeted monoclonal antibody gevokizumab (XOMA more

Market studies XOMA

• XOMA Corporation – Product Pipeline Review – 2012

  Introduction Global Market Direct’s pharmaceuticals report, “XOMA Corporation - Product Pipeline Review - 2012” provides data on the XOMA Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on d more

• Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

  GBI Research has released its pharmaceutical research, “Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market”, which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into more

• Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review

  Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review Summary Ardea Biosciences, Inc. (Ardea Biosciences) is a biotechnology company principally engaged in the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory d more

Websites XOMA